Compare Danaher Corporation (DHR) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Docusign Inc — how do they compare? Danaher Corporation trades at $219.27 (market cap $152.87B), while Docusign Inc trades at $72.03 (market cap $13.35B). The key difference: Danaher Corporation is far larger — about 11.5× Docusign Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Docusign Inc for 71 Days on average.
| DHR | DOCU | |
|---|---|---|
Market Cap | $152.87B | $13.35B |
Volume | 5,228,698 | 3,158,858 |
Sector | Health | Technology |
52-Week High | $242.05 | $73.14 |
52-Week Low | $161.91 | $41.75 |
Typical Hold Time | 69 Days | 71 Days |
Enterprise Value | $175.08B | $12.76B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
